"Solving the puzzle" of current HAART: What key strategic trials are needed?

New Microbiologica

Volumn 27, Issue 2 SUPPL. 1, 2004, Pages 127-130

  Carosi, G ^a   Torti, C ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Clinical trials; HAART; HIV; Treatment strategy

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DYSPNEA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; NEUROPSYCHOLOGY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; RASH; SALVAGE THERAPY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT REFUSAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 11844306585     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. COSSARIZZA A., MOYLE G. (2004). Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS, 18, 137-51.
2. COZZI A., SABIN C., STASZEWSKI S., HERTOGS K., MULLER A., RABENAU H., ET AL. (2000). Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis, 181, 1143-1147.
3. DESCAMPS D., FLANDRE P., CALVEZ V., PEYTAVIN G., MEIFFREDY V., COLLIN G., ET AL. (2000). Mechanisms of virologie failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA, 283, 205-211.
4. GALLEGO O., RUIZ L., VALLEJO A., FERRER E., RUBIO A., CLOSET B., ET AL. (2001). Changes in the rates of genotypic resistance to antiretroviral drugs in Spain. AIDS, 15, 1894-1896.
5. HIRSCHEL B. (2003). Beware of drug holidays before HIV salvage therapy. N Engl J Med, 349, 827-828.
6. KATLAMA C, DOMINGUEZ S, GOURLAIN K, DUVIVIER C, DELAUGERRE C, LEGRAND M, ET AL. (2004). Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomised controlled trial (ANRS 097). AIDS, 18, 217-226.
7. LAFEUILLADE A, POGGI C, HITTINGER G, COUNILLON E, EMILE D. (2003). Predictors of plasm human immunodeficiency virus type 1 RNA control after discontinuation of higly active antiretroviral therapy initiated at acute infection combined with structured treatment interruption and immune-based therapies. J Infect Dis, 188, 1426-1432.
8. LAWRENCE J, MAYERS DL, HULLSIEK KH, COLLINS GARY, ABRAMS D, REISLER RB, ET AL. (2003). Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med, 349, 837-846.
9. LONERGAN J.T. BARBER R.E. MATHEWS W.C. (2003). Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS, 17, 2495-2499.
10. MAGGIOLO F, MIGLIORINO M, MASERATI R, PAN A, RIZZI M, PROVETTONI G, ET AL. (2001). Virological and immunological responses to a once-a-day anti-retroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther, 6, 249-253.
11. MAGGIOLO F, RIPAMONTI D, GREGIS G, QUINZAN G, ARICI C, RAVASIO L, ET AL. (2003). Individualized structured treatment interruptions: results of a randomized, controlled study (BASTA). Program and abstracts of the 43rd Annual ICAAC; September 14-17 Chicago, Illinois. Abstract H-448.
12. MARTINEZ-PICADO J, NEGREDO E, RUIZ L, SHINTANI A, FUMAZ CR, ZALA C, ET AL. (2003). Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med, 139, 81-89.
13. MICHELMORE H., JEGANATHAN S., CHAN D., BATTERHAM M. (2003). Sustained HIV-1 suppression in treatment-naive patients undergoing 4- to 3- drug induction maintenance therapy (INDUMAIN). J Acquir Immune Defic Syndr, 33, 543.
14. MULLIGAN K., GRUNFELD C., TAI V.W., ET AL. (2000). Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr, 23, 345-343.
15. QUIROS-ROLDAN E., SIGNORINI S., CASTELLI F., TORTI C., PATRONI A., AIROLDI M., ET AL. (2001). Analysis of HIV-1 mutation patterns in patients failing anti-retroviral therapy. J Clin Lab Anal, 15, 43-46.
16. SHAFER R.W., SMEATON L.M., ROBBINS G.K., DE GRUTTOLA V., SNYDER S.W., D'AQUILA R.T., ET AL. (2003). Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 349, 2304-2315.
17. THE DATA COLLECTION ON ADVERSE EVENTS OF ANTI-HIV DRUGS (DAD) STUDY GROUP (2003). Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med, 349, 1993-19903.
18. VAN LETH F., HASSINK E., PHANUPHAK P., RUXRUNGTHAM K., BARALDI E., ET AL. (2004). Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet, 363, 1253-1263.
19. WALMSLEY S., BERNSTEIN B., KING M., ARRIBAS J., BEALL G., RUANE P., ET AL. (2002). Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med, 346, 2039-2046.
20. WANKE C.A., FALUTZ J.M., SHEVITZ A., PHAIR J.P., KOTLER D.P. (2002). Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis, 34, 248-259.
21. th-CROI; February 8-11, Francisco, California. Abstract 56.4.
22. WOOD E., HOGG R.S., YIP B., HARRIGAN P.R. O'SHAUGHNESSY M.V., MONTANER J.S. (2003). Effect of medication adherence on survival of HIV infected adults who start highly active anti-retroviral therapy when the CD4_ cell count is 0.200 to 0.350-109 cells/L. Ann Intern Med, 139, 810-816.